Chordoma Foundation - Systemic Therapy Table
 Share
The version of the browser you are using is no longer supported. Please upgrade to a supported browser.Dismiss

 
View only
 
 
ABDJKLMNOPQRSTUVWXYZAAABACADAE
1
Systemic therapy classMechanism of actionDrugBrand name
Available off label
Open clinical trial(s)
2
Targeted TherapyEGFR inhibitorAfatinibGilotrifYesYes
3
CetuximabErbituxYesYes
4
GefitinibIressa
Yes (not in the U.S.)
5
ErlotinibTarcevaYesYes
6
LapatinibTykerbYes
7
8
CDK4/6 inhibitorPalbociclibIbranceYesYes
9
Yes
10
11
mTOR inhibitorSirolimusRapamuneYes
12
EverolimusAfinitorYes
13
TemsirolimusToricelYesYes
14
15
PI3K inhibitorTaselisibYes
16
17
EZH2 inhibitorTazemetostatYes
18
19
PDGFR inhibitorImatinibGleevecYes
20
SorafenibNexavarYes
21
SunitinibSutentYesYes
22
23
VEGF inhibitorRegorafenibStivargaYesYes
24
Yes
25
PazopanibVotrientYes
26
BevacizumabAvastinYes
27
28
Immune Checkpoint InhibitorPD-1/PD-L1 inhibitorAtezolizumabTecentriqYes
29
AvelumabBavencioYes
30
DurvalumabImfinziYesYes
31
NivolumabOpdivoYesYes
32
Yes
33
Yes
34
Yes
35
PembrolizumabKeytrudaYesYes
36
Yes
37
M7824Yes
38
39
Therapeutic VaccineAnti-brachyury vaccineGI-6301 vaccineYes
40
41
Autologous tumor vaccine
MVX-ONCO-1Yes
42
43
Oncolytic BacteriaBacteriolysisC. Novyi NTYes (on hold)
44
45
46
Criteria for inclusion in this table:
1. Mechanism that the Chordoma Foundation Medical Advisory Board has recommended be explored in a clinical trial for chordoma
2. Any mechanism that has been studied in a Phase 2 trial for chordoma
3. The drugs/therapies listed for each mechanism are either currently being studied in a clinical trial that is enrolling chordoma patients or are available off-label
47
48
© 2018 Chordoma Foundation
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
Loading...
Main menu